AI Article Synopsis
- High-dose methotrexate is used to treat osteosarcoma but can cause serious kidney damage.
- Glucarpidase (carboxypeptidase-G2) was approved in 2012 to help treat toxic methotrexate levels.
- In two patients with delayed methotrexate clearance, the study suggests that multiple doses of glucarpidase may be needed along with other treatments like dialysis for effective management of kidney injury.
Article Abstract
High-dose methotrexate has been a treatment for osteosarcoma; however, its nephrotoxic effects are considerable. Carboxypeptidase-G2 (glucarpidase) was approved by the US Food and Drug Administration in 2012 for treatment of toxic methotrexate levels. We report our experience using glucarpidase under compassionate use before Food and Drug Administration approval in 2 patients who had delayed methotrexate clearance and prolonged kidney injury despite glucarpidase administration. Our results show that patients with methotrexate toxicity may require repeated doses of glucarpidase in addition to supportive measures, such as dialysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPH.0000000000001058 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!